新辅助化疗用于局部发达的头部和部状细胞癌 - 它仍然相关吗? 在印度的瘤学家中进行实践模式调查
Anis Bandyopadhyay1, Uddiptya Goswami1, Poulomi Ghosh1
1Department of Radiotherapy, NRS Medical College, Kolkata, West Bengal, India.
Journal of cancer research and therapeutics
|October 3, 2023
概括
新辅助化疗 (NACT) 广泛用于高级头癌,尽管有争议的证据. 瘤学家使用NACT来改善治疗时间和切除,尽管建议同时进行化疗.
科学领域:
- 在瘤学瘤学.
- 头部和部癌症 治疗 治疗
- 化疗研究 化疗研究
背景情况:
- 同时化学辐射是局部发达的头部 (H&N) 状细胞癌的标准.
- 新辅助化疗 (NACT) 的使用是有争议的,对改善局部区域控制或生存的证据有限.
- 尽管存在争议,但NACT经常被瘤学家使用.
研究的目的:
- 调查NACT在局部晚期H&N癌症中的使用频率,模式和目标.
- 了解印度辐射,医学和外科瘤学家之间的实践模式.
- 为了确定推动NACT采用的感知好处.
主要方法:
- 在印度各地的瘤学家中进行了一项在线调查.
- 一个基于移动应用程序的问卷调查评估了NACT的使用模式和首选的方法.
- 分析了150项已完成调查的数据.
主要成果:
- 连续化学辐射,主要是NACT与TPF疗法,其次是辐射,是最常见的方法 (61%).
- 使用NACT的主要原因包括"购买治疗时间" (20%) 和实现R0切除 (19.2%).
- 医疗和放射瘤学家对NACT使用的偏好相似,超过一半的人更喜欢至少两次循环.
结论:
- 尽管I级证据表明与并发化学辐射相比,NACT的结果可能较差,但它仍然被广泛使用.
- 感知到的好处包括改善治疗时间,R0切除率,瘤下降阶段,以及更好地耐受随后的化疗辐射.
- 广泛使用凸显了先进的H&N癌症管理中的证据和临床实践之间的差距.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Survival Analysis
380
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
380
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
184
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
184
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


